Dr. Isacson will continue the role of leader of the PD IPS consortium that he began in 2009, when the ARRA GO grants (RC2s) funded the PD, ALS and HD consortia. His experience and leadership will strengthen the ability of the PD IPS consortium to achieve the goals set out in the RFA for this U24 grant. This PD iPS Consortium will now be organized into three Project Cores, a) Clinical and Genetic Core (Z. Wszoiek, core PI), b) Differentiation and Reporter Core (L. Studer and D. Krainc, core Pis), c) Cell Function and Pathophysiology Core (T. Dawson, core PI). These three cores will be supported by the research resource cores: Administration (O. Isacson, core PI) and the Reprogramming contract research organizations (CROs) (Harvard Stem Cell Institute and New York Stem Cell Foundation) (see letters of collaboration). (For overview of organization, see Fig. 1, Introduction). The cores include research studies at eight separate institutions (McLean/Harvard, Columbia, Mayo-Jacksonville, Memorial Sloan Keftering, Massachusetts General Hospital/Harvard, Johns Hopkins University, University of Pennsylvania and Northwestern University. In order to foster the synergies and lines of communication necessary for the successful achievement of the scientific and technical challenges to achieving the consortium goals and timelines, the Administrative Core will provide the organization and support for the administration of this U24 grant. The Consortium Director, Prof Ole Isacson, is responsible for ensuring that coordination and core functions are appropriately managed. Dr. Isacson's expertise in stem cell use exceeds a decade, and he has productively directed NIH-funded Centers and Programs, including the recent RC2 GO grant that currently funds this PD IPS Consortium. Because the interactions between the members of this Consortium are essential to the accomplishment of the Consortium goals, Dr. Isacson will hold a conference call every 2 months between all of the Core Pis and the members of the Executive Science Committee (see Fig. 2, Introduction). He will promote the continuous cooperation between investigators, and the sending of cells for deposit to Coriell. On the administrative day-to-day detail, Ms. Sandra Pohlman has been the chief administrator of the Center for Neuroregeneration Research at McLean Hospital/Harvard Medical School for over 10 years. Her role is to manage resources and funds, and ensure proper accounting and spending according to the research plan and research cost categories. Her involvement as an Administrator is exemplified by the cooperative agreements involved. She has carried out such activities previously for large Center grants and the current PD IPS consortium. Ms. Pohlman serves as the coordinator for communication between the investigators on this proposal, their grants administrators and sponsored research offices for preparation and administration of budgets and research reports.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mclean Hospital
United States
Zip Code
Mazzulli, Joseph R; Zunke, Friederike; Tsunemi, Taiji et al. (2016) Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. J Neurosci 36:7693-706
Mazzulli, Joseph R; Zunke, Friederike; Isacson, Ole et al. (2016) α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A 113:1931-6
Chung, Sun Young; Kishinevsky, Sarah; Mazzulli, Joseph R et al. (2016) Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation. Stem Cell Reports 7:664-677
Sanders, Laurie H; Laganiere, Josee; Cooper, Oliver et al. (2014) LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol Dis 62:381-6
Sundal, Christina; Fujioka, Shinsuke; Van Gerpen, Jay A et al. (2013) Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism Relat Disord 19:869-77
Sundberg, Maria; Bogetofte, Helle; Lawson, Tristan et al. (2013) Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 31:1548-62
Miller, Justine D; Ganat, Yosif M; Kishinevsky, Sarah et al. (2013) Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13:691-705
Cooper, Oliver; Seo, Hyemyung; Andrabi, Shaida et al. (2012) Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 4:141ra90